Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia

Torgalsbøen, Anne‐Kari; Mohn, Christine; Rund, Bjørn Rishovd

doi:10.1016/j.psychres.2014.01.031

Cited by 46 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…69 Another 6-month longitudinal study examined neurocognitive predictors of remission in patients with FEP, reporting that only attention/ vigilance at baseline was a predictor of remission of FEP amongst the seven Measurement and Treatment Research to Improve Cognition in Schizophrenia cognitive domains. 70 Given that attention/vigilance has a crucial role in predicting favorable outcomes in patents with schizophrenia, AMPA positive modulators in particular, which may have beneficial effects on attention/vigilance, might have a role in improving functional outcome.…”

Section: Findings By Analyses Of Individual Drugs and Subgroup Analysesmentioning

confidence: 99%

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

Hypofunction of N-methyl-D-aspartate (NMDA) receptors has been proposed to have an important role in the cognitive impairments observed in schizophrenia. Although glutamate modulators may be effective in reversing such difficult-to-treat conditions, the results of individual studies thus far have been inconsistent. We conducted a systematic review and meta-analysis to examine whether glutamate positive modulators have beneficial effects on cognitive functions in patients with schizophrenia. A literature search was conducted to identify double-blind randomized placebo-controlled trials in schizophrenia or related disorders, using Embase, Medline, and PsycINFO (last search: February 2015). The effects of glutamate positive modulators on cognitive deficits were evaluated for overall cognitive function and eight cognitive domains by calculating standardized mean differences (SMDs) between active drugs and placebo added to antipsychotics. Seventeen studies (N = 1391) were included. Glutamate positive modulators were not superior to placebo in terms of overall cognitive function (SMD = 0.08, 95% confidence interval = − 0.06 to 0.23) (11 studies, n = 858) nor each of eight cognitive domains (SMDs = − 0.03 to 0.11) (n = 367-940) in this population. Subgroup analyses by diagnosis (schizophrenia only studies), concomitant antipsychotics, or pathway of drugs to enhance the glutamatergic neurotransmission (glycine allosteric site of NMDA receptors or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors) suggested no procognitive effect of glutamate positive modulators. Further, no effect was found in individual compounds on cognition. In conclusion, glutamate positive modulators may not be effective in reversing overall cognitive impairments in patients with schizophrenia as adjunctive therapies.

show abstract

Section: Findings By Analyses Of Individual Drugs and Subgroup Analysesmentioning

confidence: 99%

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The results also have showed that nonremitted first-episode schizophrenia patients performed worse in verbal memory domain and there is a positive correlation between bilateral parahippocampal cortex volume and verbal memory performance. These results are in line with Chang et al [14], and Benoit et al [15], but are not confirmed by Torgalsbøen et al [13]. Notwithstanding, Torgalsbøen et al [13] is an outgoing study, and is recommended to wait for the results from the next follow-up before drawing conclusions.…”

Section: First-episode Psychosis/schizophreniamentioning

confidence: 47%

“…These results are in line with Chang et al [14], and Benoit et al [15], but are not confirmed by Torgalsbøen et al [13]. Notwithstanding, Torgalsbøen et al [13] is an outgoing study, and is recommended to wait for the results from the next follow-up before drawing conclusions. In addition, chronic patients with an average (or higher) verbal intelligence appears to be more likely to reach the status of clinical remission in schizophrenia [3].…”

Section: First-episode Psychosis/schizophreniamentioning

confidence: 47%

“…Hospitalized EOS subjects (aged [13][14][15][16][17][18] with first episode at the introduction of pharmacotherapy (FES T1) and after the resolution of psychotic symptoms at psychopathological symptoms mean 7 weeks (FES T2) and Stable Outpatients (SO) group (aged 16-19 with diagnosis of early-onset schizophrenia, with at least one previous hospitalization and illness duration of minimum one year) were matched with healthy controls. Severity of symptoms was assessed with Positive and Negative Syndrome Scale (PANSS), total score and positive, negative and general psychopathology subscales scores were analyzed, however any formalized definition of remission was applied.…”

Section: Early-onset Schizophrenia (Eos)mentioning

confidence: 99%

“…Torgalsbøen et al [13], conducted a long-term prospective study of first-episode schizophrenia patients (FES) assessing the relationship between neurocognition and remission in firstepisode schizophrenia patients with follow-up points at baseline and after 6 months. Their results showed that more than half of the group of first-episode patients where in remission, neurocognitive baseline measure of attention (from the MATRICS Consensus Cognitive Battery) predicted remission status at follow-up and in the early course of the illness, and remitted patients had significantly higher scores on overall neurocognitive function than those not fulfilling the remission criteria.…”

Section: First-episode Psychosis/schizophreniamentioning

confidence: 99%

See 2 more Smart Citations

From “What” to “How”: The Effort to Fill the Gaps in Understanding Cognitive Processes Underpinning Remission in Schizophrenia

Rabanea-Souza¹

2016

Acta Psychopathol

View full text Add to dashboard Cite

Introduction: The accumulation of robust evidence culminated in the establishment of the cognitive deficits as a core symptom of Schizophrenia (SCZ). To date, there has been reliable evidence that cognitive deficits are associated with poor symptomatic outcomes in SCZ. Nevertheless, they have not been incorporated in definitions of remission and a systematic understanding of how cognition contributes to remission is still lacking. Although the standardized remission in SCZ criteria proposed in 2005 has encouraged studies to understand the role of cognitive function in symptomatic remission from SCZ, most investigations were cross-sectional and have studied samples of chronically ill patients. The purpose of the present study was to bring together the efforts of recent follow-up studies in early in earlier stages of the disease to fill the gap in the literature on understanding how cognitive impairment is related to remission.

show abstract

Shifting the focus toward rare variants in schizophrenia to close the gap from genotype to phenotype

Bustamante

Herrera

Gaspar

et al. 2017

American J of Med Genetics Pt B

View full text Add to dashboard Cite

Schizophrenia (SZ) is a disorder with a high heritability and a complex architecture. Several dozen genetic variants have been identified as risk factors through genome-wide association studies including large population-based samples. However, the bulk of the risk cannot be accounted for by the genes associated to date. Rare mutations have been historically seen as relevant only for some infrequent, Mendelian forms of psychosis. Recent findings, however, show that the subset of patients that present a mutation with major effect is larger than expected. We discuss some of the molecular findings of these studies. SZ is clinically and genetically heterogeneous. To identify the genetic variation underlying the disorder, research should be focused on features that are more likely a product of genetic heterogeneity. Based on the phenotypical correlations with rare variants, cognition emerges as a relevant domain to study. Cognitive disturbances could be useful in selecting cases that have a higher probability of carrying deleterious mutations, as well as on the correct ascertainment of sporadic cases for the identification of de novo variants.

show abstract

Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia

Cited by 46 publications

References 28 publications

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials

From “What” to “How”: The Effort to Fill the Gaps in Understanding Cognitive Processes Underpinning Remission in Schizophrenia

Shifting the focus toward rare variants in schizophrenia to close the gap from genotype to phenotype

Contact Info

Product

Resources

About